Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3605) 3605
Book Review (630) 630
Publication (145) 145
Newsletter (99) 99
Magazine Article (53) 53
Newspaper Article (41) 41
Conference Proceeding (7) 7
Trade Publication Article (7) 7
Book Chapter (6) 6
Dissertation (5) 5
Book / eBook (2) 2
Streaming Video (2) 2
Data Set (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3069) 3069
female (3025) 3025
humans (2998) 2998
levonorgestrel (2161) 2161
adult (1700) 1700
levonorgestrel - administration & dosage (1685) 1685
obstetrics & gynecology (1483) 1483
contraceptive agents, female - administration & dosage (818) 818
pregnancy (799) 799
adolescent (770) 770
women (726) 726
contraception (668) 668
levonorgestrel - adverse effects (662) 662
middle aged (610) 610
population (484) 484
intrauterine devices, medicated (472) 472
obstetrics and gynecology (461) 461
oral contraceptives (444) 444
abridged index medicus (420) 420
drug implants (410) 410
young adult (383) 383
ethinyl estradiol - administration & dosage (381) 381
birth control (366) 366
contraceptive agents, female - adverse effects (352) 352
levonorgestrel - pharmacology (339) 339
emergency contraception (328) 328
time factors (322) 322
levonorgestrel - therapeutic use (318) 318
contraceptives, oral, combined - administration & dosage (299) 299
prospective studies (299) 299
norgestrel - administration & dosage (295) 295
ethinyl estradiol (289) 289
treatment outcome (287) 287
reproductive biology (284) 284
contraceptive drug implants (272) 272
animals (249) 249
medicine, general & internal (236) 236
contraceptives (235) 235
pharmacology & pharmacy (226) 226
dosage and administration (221) 221
intrauterine devices, medicated - adverse effects (221) 221
male (221) 221
estradiol (213) 213
united states (210) 210
health aspects (209) 209
menorrhagia (208) 208
contraceptives, oral, combined - adverse effects (205) 205
risk factors (204) 204
intrauterine devices (201) 201
contraception - methods (199) 199
analysis (192) 192
risk (192) 192
follow-up studies (188) 188
endometrium - drug effects (183) 183
progesterone (183) 183
ethinyl estradiol - adverse effects (181) 181
estrogen (172) 172
oral-contraceptives (169) 169
contraceptives, oral, synthetic - administration & dosage (166) 166
efficacy (161) 161
endocrinology & metabolism (161) 161
menorrhagia - drug therapy (158) 158
research (158) 158
contraceptives, oral, combined - pharmacology (157) 157
pharmacokinetics (156) 156
public, environmental & occupational health (154) 154
administration, oral (153) 153
ethinyl estradiol - pharmacology (151) 151
desogestrel (150) 150
yuzpe regimen (150) 150
contraceptive agents, female - pharmacology (148) 148
menstruation (148) 148
progestins - administration & dosage (148) 148
usage (147) 147
endometrium (144) 144
mifepristone (144) 144
patient satisfaction (144) 144
norplant (140) 140
hormone replacement therapy (139) 139
levonorgestrel - pharmacokinetics (138) 138
contraceptive agents, female - therapeutic use (137) 137
drug administration schedule (137) 137
hysterectomy (136) 136
norgestrel - pharmacology (136) 136
device (134) 134
estradiol - blood (134) 134
estradiol - administration & dosage (133) 133
dose-response relationship, drug (129) 129
ethinylestradiol (127) 127
levonorgestrel intrauterine system (127) 127
levonorgestrel-releasing intrauterine system (127) 127
postmenopausal women (126) 126
delayed-action preparations (125) 125
norgestrel - adverse effects (125) 125
womens health (125) 125
ulipristal acetate (124) 124
progesterone congeners - administration & dosage (121) 121
contraception, postcoital - methods (120) 120
progesterone - blood (120) 120
intrauterine device (119) 119
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3638) 3638
French (44) 44
Chinese (34) 34
German (28) 28
Spanish (17) 17
Danish (7) 7
Polish (7) 7
Bulgarian (6) 6
Dutch (6) 6
Portuguese (6) 6
Russian (4) 4
Finnish (3) 3
Italian (3) 3
Japanese (3) 3
Swedish (3) 3
Croatian (2) 2
Czech (2) 2
Hungarian (2) 2
Norwegian (2) 2
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration–approved duration
by McNicholas, Colleen, DO, MSCI and Swor, Erin, MD and Wan, Leping, MPH and Peipert, Jeffrey F., MD, PhD
American Journal of Obstetrics and Gynecology, ISSN 0002-9378, 2017, Volume 216, Issue 6, pp. 586.e1 - 586.e6
Background The subdermal contraceptive implant and the 52-mg levonorgestrel intrauterine device are currently Food and Drug Administration approved for 3 and 5... 
Obstetrics and Gynecology | effectiveness | prolonged use | implant | intrauterine device | Food and Drug Administration–approved duration | Body Mass Index | Prospective Studies | Desogestrel - adverse effects | United States | Humans | Middle Aged | Drug Implants | Intrauterine Devices, Medicated | Pregnancy | Young Adult | Desogestrel - administration & dosage | Time Factors | Levonorgestrel - administration & dosage | Levonorgestrel - adverse effects | Pregnancy, Unplanned | Adolescent | Adult | Female | Contraceptive Agents, Female | United States Food and Drug Administration | Cohort Studies | Contraceptive drug implants | Medical colleges | Medical research | Usage | Analysis | Levonorgestrel | Medicine, Experimental | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. food and drug administration-approved duration
by McNicholas, Colleen and Maddipati, Ragini and Zhao, Qiuhong and Swor, Erin and Peipert, Jeffrey F
Obstetrics and Gynecology, ISSN 0029-7844, 03/2015, Volume 125, Issue 3, pp. 599 - 604
OBJECTIVE: To evaluate the effectiveness of the contraceptive implant and the 52-mg hormonal intrauterine device (IUD) in women using the method beyond the... 
WOMEN | ACTING REVERSIBLE CONTRACEPTION | CLINICAL-TRIAL | EFFICACY | UNINTENDED PREGNANCY | ADOLESCENTS | NO-COST | IUDS | SUBDERMAL IMPLANTS | BENEFITS | OBSTETRICS & GYNECOLOGY | Prospective Studies | United States | Humans | Contraceptive Agents, Female - administration & dosage | Intrauterine Devices, Medicated | Young Adult | Desogestrel - administration & dosage | Time Factors | Levonorgestrel - administration & dosage | Adolescent | Adult | Female | United States Food and Drug Administration | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Quantitative determination of levonorgestrel in beagle dog plasma after vaginal administration of intravaginal ring by high‐performance liquid chromatography–tandem mass spectrometry
by Liu, Zhenqi and Qiu, Shunchen and Gu, Yiqun and Ning, Meiying
Biomedical Chromatography, ISSN 0269-3879, 12/2018, Volume 32, Issue 12, pp. e4367 - n/a
A specific and sensitive high‐performance liquid chromatography–tandem mass spectrometry method that could be used to determine the concentration of... 
intravaginal ring | pharmacokinetic | LC–MS/MS | levonorgestrel | DRUG | CHEMISTRY, ANALYTICAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIOCHEMICAL RESEARCH METHODS | LC-MS/MS | IMPLANT | WOMEN | PHARMACOLOGY & PHARMACY | PHARMACOKINETIC EVALUATION | ETHINYLESTRADIOL | Reproducibility of Results | Chromatography, High Pressure Liquid - methods | Drug Stability | Contraceptive Devices, Female | Administration, Intravaginal | Linear Models | Animals | Levonorgestrel - pharmacokinetics | Levonorgestrel - administration & dosage | Levonorgestrel - blood | Sensitivity and Specificity | Dogs | Female | Tandem Mass Spectrometry - methods | Contraceptive drug implants | Liquefied natural gas | Mass spectrometry | Analysis | High performance liquid chromatography | Levonorgestrel | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy
by Ugaonkar, Shweta R and Wesenberg, Asa and Wilk, Jolanta and Seidor, Samantha and Mizenina, Olga and Kizima, Larisa and Rodriguez, Aixa and Zhang, Shimin and Levendosky, Keith and Kenney, Jessica and Aravantinou, Meropi and Derby, Nina and Grasperge, Brooke and Gettie, Agegnehu and Blanchard, James and Kumar, Narender and Roberts, Kevin and Robbiani, Melissa and Fernández-Romero, José A and Zydowsky, Thomas M
Journal of Controlled Release, ISSN 0168-3659, 09/2015, Volume 213, pp. 57 - 68
Women urgently need a self-initiated, multipurpose prevention technology (MPT) that simultaneously reduces their risk of acquiring HIV-1, HSV-2, and HPV... 
Efficacy | Core–matrix design | Contraception | Multipurpose prevention technology | Microbicides | Intravaginal ring | Core-matrix design | CLINICAL-TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | CHEMISTRY, MULTIDISCIPLINARY | VAGINAL RING | TENOFOVIR DISOPROXIL FUMARATE | IN-VITRO | TYPE-2 INFECTION | COMBINATION MICROBICIDE | PHARMACOLOGY & PHARMACY | REVERSE-TRANSCRIPTASE INFECTION | HUMAN-PAPILLOMAVIRUS INFECTION | PROTECTS MACAQUES | Contraceptive Agents, Female - pharmacology | HIV Infections - prevention & control | Drug Delivery Systems - instrumentation | Antiviral Agents - pharmacokinetics | Urea - pharmacokinetics | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Contraceptive Agents, Female - administration & dosage | Pyridines - pharmacokinetics | Administration, Intravaginal | Human papillomavirus 16 - drug effects | Macaca mulatta | Equipment Design | Herpes Genitalis - prevention & control | Levonorgestrel - pharmacokinetics | Carrageenan - pharmacology | Urea - analogs & derivatives | Zinc Acetate - administration & dosage | Contraceptive Agents, Female - pharmacokinetics | Female | Herpesvirus 2, Human - drug effects | Urea - administration & dosage | Cell Line | Antiviral Agents - pharmacology | Levonorgestrel - pharmacology | Pyridines - administration & dosage | HIV-1 - drug effects | Carrageenan - pharmacokinetics | Contraceptive Devices, Female - virology | Antiviral Agents - administration & dosage | Pregnancy | Animals | Levonorgestrel - administration & dosage | Papillomavirus Infections - prevention & control | Zinc Acetate - pharmacokinetics | Zinc Acetate - pharmacology | Pyridines - pharmacology | HeLa Cells | Urea - pharmacology | Carrageenan - administration & dosage | Prevention | Contraceptives | Carrageenin | Pregnant women | Elastomers | Liquefied natural gas | HIV (Viruses) | Warships | Index Medicus | intravaginal ring | multipurpose prevention technology | core-matrix design | contraception | microbicides | efficacy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database
by Hasegawa, Shiori and Matsui, Toshinobu and Hane, Yuuki and Abe, Junko and Hatahira, Haruna and Motooka, Yumi and Sasaoka, Sayaka and Fukuda, Akiho and Naganuma, Misa and Hirade, Kouseki and Takahashi, Yukiko and Kinosada, Yasutomi and Nakamura, Mitsuhiro
PLoS ONE, ISSN 1932-6203, 07/2017, Volume 12, Issue 7, pp. e0182045 - e0182045
Combined estrogen-progestin preparations (CEPs) are associated with thromboembolic (TE) side effects. The aim of this study was to evaluate the incidence of TE... 
HORMONAL CONTRACEPTION | SYSTEM DATABASE | SIGNAL-DETECTION | VENOUS THROMBOEMBOLISM | MYOCARDIAL-INFARCTION | THROMBOSIS | ODDS RATIO | MULTIDISCIPLINARY SCIENCES | ORAL-CONTRACEPTIVE USE | SWEDISH WOMEN | RISK | Norgestrel - administration & dosage | Thromboembolism - chemically induced | Desogestrel - adverse effects | Humans | Middle Aged | Progestins - adverse effects | Male | Norgestrel - adverse effects | Estrogens - adverse effects | Norethindrone - administration & dosage | Young Adult | Ethinyl Estradiol - adverse effects | Drug-Related Side Effects and Adverse Reactions - genetics | Norethindrone - adverse effects | Adult | Female | Ethinyl Estradiol - administration & dosage | Contraceptives, Oral, Combined - administration & dosage | Odds Ratio | Child | Databases, Factual | Androstenes - adverse effects | Adverse Drug Reaction Reporting Systems | Japan | Androstenes - administration & dosage | Contraceptives, Oral, Combined - adverse effects | Desogestrel - administration & dosage | Levonorgestrel - administration & dosage | Levonorgestrel - adverse effects | Progestins - administration & dosage | Adolescent | Estrogens - administration & dosage | Progestational hormones | Thromboembolism | Health aspects | Risk factors | Estrogen | Drugs | Ethinylestradiol | Medical equipment | Medical devices | Anemia | Estrogens | Cases (containers) | Risk analysis | Data mining | Patients | Estradiol | Data bases | Incidence | Birth control | Sex hormones | Side effects | Databases | Progestin | Health risk assessment | Pharmaceuticals | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants
by Devineni, Damayanthi and Manitpisitkul, Prasarn and Vaccaro, Nicole and Bernard, Apexa and Skee, Donna and Mamidi, Rao N.V.S and Tian, Hong and Weiner, Sveta and Stieltjes, Hans and Sha, Sue and Rothenberg, Paul
International Journal of Clinical Pharmacology and Therapeutics, ISSN 0946-1965, 01/2015, Volume 53, Issue 1, pp. 41 - 53
Objective: Drug-drug interactions between canagliflozin, a sodium glucose co-transporter 2 inhibitor approved for the management of type-2 diabetes mellitus,... 
Warfarin | Oral contraceptive | Canagliflozin | Digoxin | Drug-drug interaction | LEVONORGESTREL | MANAGEMENT | VOLUNTEERS | PHARMACODYNAMICS | digoxin | warfarin | P-GLYCOPROTEIN | TRANSPORT | THERAPY | METABOLISM | canagliflozin | PHARMACOLOGY & PHARMACY | drug-drug interaction | oral contraceptive | EMPAGLIFLOZIN | Ethinyl Estradiol - blood | Anticoagulants - administration & dosage | Ethinyl Estradiol - pharmacokinetics | Thiophenes - adverse effects | Area Under Curve | Contraceptives, Oral, Combined - pharmacokinetics | Humans | Middle Aged | Half-Life | Male | Metabolic Clearance Rate | Thiophenes - administration & dosage | Healthy Volunteers | Warfarin - administration & dosage | Young Adult | Drug Dosage Calculations | Drug Interactions | Polypharmacy | Hypoglycemic Agents - administration & dosage | Levonorgestrel - pharmacokinetics | Adult | Female | Ethinyl Estradiol - administration & dosage | Contraceptives, Oral, Combined - administration & dosage | Digoxin - blood | Glucosides - adverse effects | Drug Administration Schedule | Risk Assessment | Sodium-Glucose Transporter 2 - metabolism | Cardiotonic Agents - pharmacokinetics | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Anticoagulants - blood | Digoxin - pharmacokinetics | Warfarin - pharmacokinetics | Cross-Over Studies | International Normalized Ratio | Cardiotonic Agents - administration & dosage | Blood Coagulation - drug effects | Digoxin - administration & dosage | Glucosides - administration & dosage | Cardiotonic Agents - blood | Levonorgestrel - administration & dosage | Levonorgestrel - blood | Warfarin - blood | Anticoagulants - pharmacokinetics | Hypoglycemic Agents - adverse effects | Contraceptives, Oral, Combined - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture
by Brache, V and Cochon, L and Jesam, C and Maldonado, R and Salvatierra, A.M and Levy, D.P and Gainer, E and Croxatto, H.B
Human Reproduction, ISSN 0268-1161, 9/2010, Volume 25, Issue 9, pp. 2256 - 2263
BACKGROUND Current methods of hormonal emergency contraception (EC) are ineffective in preventing follicular rupture when administered in the advanced... 
ulipristal acetate | LH surge | emergency contraception | follicular rupture | SEXUAL INTERCOURSE | LEVONORGESTREL | MECHANISMS | MIFEPRISTONE | OBSTETRICS & GYNECOLOGY | TRIAL | REPRODUCTIVE BIOLOGY | YUZPE REGIMEN | OVULATION | PROGESTERONE-RECEPTOR | OVARIAN-FUNCTION | Estradiol - blood | Contraception, Postcoital - adverse effects | Humans | Norpregnadienes - administration & dosage | Progesterone - blood | Statistics as Topic | Ovarian Follicle - diagnostic imaging | Receptors, Progesterone - antagonists & inhibitors | Young Adult | Ovarian Follicle - drug effects | Time Factors | Contraceptives, Postcoital, Synthetic - administration & dosage | Ultrasonography | Adult | Female | Contraception, Postcoital - methods | Norpregnadienes - adverse effects | Ovulation Inhibition - drug effects | Double-Blind Method | Luteinizing Hormone - blood | Ovarian Follicle - anatomy & histology | Norpregnadienes - therapeutic use | Follicular Phase - drug effects | Organ Size | Follicular Phase - blood | Cross-Over Studies | Contraceptives, Postcoital, Synthetic - adverse effects | Contraceptives, Postcoital, Synthetic - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial
by von Hertzen, Helena and Piaggio, Gilda and Peregoudov, Alexandre and Ding, Juhong and Chen, Junling and Song, Si and Bártfai, György and Ng, Ernest and Gemzell-Danielsson, Kristina and Oyunbileg, Amindavaa and Wu, Shangchun and Cheng, Weiyu and Lüdicke, Frank and Pretnar-Darovec, Alenka and Kirkman, Rosemary and Mittal, Suneeta and Khomassuridze, Archil and Apter, Dan and WHO Res Grp Post-ovulatory Methods and WHO Research Group on Post-ovulatory Methods of Fertility Regulation
The Lancet, ISSN 0140-6736, 2002, Volume 360, Issue 9348, pp. 1803 - 1810
A single 10 mg dose of mifepristone, and two 0·75 mg doses of levonorgestrel 12 h apart, are effective for emergency contraception. Because no studies had... 
MEDICINE, GENERAL & INTERNAL | YUZPE REGIMEN | Contraceptives, Oral, Synthetic - administration & dosage | World Health Organization | Double-Blind Method | Drug Administration Schedule | Levonorgestrel - administration & dosage | Humans | Contraceptives, Postcoital, Synthetic - administration & dosage | Emergencies | Adult | Female | Mifepristone - administration & dosage | Evaluation | Mifepristone | Dosage and administration | Contraceptives, Postcoital | Levonorgestrel | Drug therapy | Birth control | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Effect of vaginal administration of misoprostol before intrauterine contraceptive insertion following previous insertion failure: a double blind RCT
by Bahamondes, M. Valeria and Espejo-Arce, Ximena and Bahamondes, Luis
Human Reproduction, ISSN 0268-1161, 08/2015, Volume 30, Issue 8, pp. 1861 - 1866
STUDY QUESTION Is pretreatment with misoprostol useful in insertion of intrauterine contraceptives (IUCs) after insertion failure at the first attempt? SUMMARY... 
insertion failure | levonorgestrel-releasing intrauterine system | intrauterine contraceptives | copper intrauterine device | misoprostol | REPRODUCTIVE BIOLOGY | NULLIPAROUS WOMEN | DEVICE INSERTION | OBSTETRICS & GYNECOLOGY | Double-Blind Method | Contraceptive Agents - administration & dosage | Contraceptive Agents - therapeutic use | Humans | Misoprostol - administration & dosage | Administration, Intravaginal | Intrauterine Devices, Medicated | Retreatment | Levonorgestrel - administration & dosage | Levonorgestrel - therapeutic use | Adult | Female | Misoprostol - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Interventions for emergency contraception
by Shen, Jie and Che, Yan and Showell, Emily and Chen, Ke and Cheng, Linan
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2019, Volume 2019, Issue 1, pp. CD001324 - CD001324
Background Emergency contraception (EC) is using a drug or copper intrauterine device (Cu-IUD) to prevent pregnancy shortly after unprotected intercourse.... 
NORGESTREL COMBINATION | MEDICINE, GENERAL & INTERNAL | POST-COITAL CONTRACEPTION | ETHINYL ESTRADIOL | EFFICACY | MIFEPRISTONE 10 MG | YUZPE REGIMEN | ORAL LEVONORGESTREL | ULIPRISTAL ACETATE | IDENTIFY WOMEN | RANDOMIZED CONTROLLED-TRIAL | Norpregnadienes - adverse effects | Drug Administration Schedule | Intrauterine Devices, Copper - adverse effects | Contraceptives, Postcoital - adverse effects | Contraception, Postcoital - adverse effects | Humans | Estradiol - administration & dosage | Intrauterine Devices, Medicated - adverse effects | Norpregnadienes - administration & dosage | Randomized Controlled Trials as Topic | Pregnancy | Mifepristone - adverse effects | Levonorgestrel - administration & dosage | Levonorgestrel - adverse effects | Contraceptives, Postcoital - administration & dosage | Unsafe Sex | Estradiol - adverse effects | Female | Contraception, Postcoital - methods | Pregnancy Rate | Mifepristone - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights